The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Evolution of Tuberculosis Control and Prospects for Reducing Tuberculosis Incidence, Prevalence, and Deaths Globally
Abstract
CONTEXT: The United Nations Millennium Development Goals (MDGs) are stimulating more rigorous evaluations of the impact of DOTS (the WHO-recommended approach to tuberculosis control based on 5 essential elements) and other possible strategies for tuberculosis (TB) control. OBJECTIVE: To evaluate the prospects for detecting 70% of new sputum smear-positive cases and successfully treating 85% of these by the end of 2005, for reducing TB incidence, and for halving TB prevalence and deaths globally between 1990 and 2015, as specified by the MDGs. DATA SOURCES: TB case notifications (1980-2003) from DOTS and non-DOTS programs and cohort treatment outcomes (1994-2002) reported annually to the World Health Organization (WHO) by up to 200 countries, TB death registrations, and prevalence surveys of infection and disease. STUDY SELECTION: Case notification series that reflect trends in incidence, treatment outcomes from DOTS cohorts, death statistics from countries with WHO-validated vital registration systems, and national prevalence surveys of infection and disease. DATA EXTRACTION: Case reports, treatment outcomes, prevalence surveys, and death registrations from WHO's global TB database covering 1990-2003 to estimate TB incidence, prevalence, and death rates through 2015 for 9 epidemiologically different world regions. DATA SYNTHESIS: TB incidence increased globally in 2003, but incidence, prevalence, and death rates were approximately stable or decreased in 7 of 9 regions. The exceptions were regions of Africa with low (<4% in adults 15-49 years) and high rates (> or =4%) of HIV infection. The global detection rate of new smear-positive cases by DOTS programs increased from 11% in 1995 to 45% in 2003 (with the lowest case-detection rates in Eastern Europe and the highest rates in the Western Pacific) and could reach 60% by 2005. More than 17 million patients were treated in DOTS programs between 1994 and 2003, with overall treatment success rates more than 80% since 1998. In 2003, overall reported treatment success was 82%, with much variation among regions. The highest rates were reported in the Western Pacific region (89%) and lowest rates in African countries with high and low HIV infection rates (71% and 74%, respectively), in established market economies (77%), and in Eastern Europe (75%). To halve the prevalence rate by 2015, TB control programs must reach global targets for detection (70%) and treatment success (85%) and also reduce the incidence rate by at least 2% annually. To halve the death rate, incidence must decrease more steeply, by at least 5% to 6% annually. CONCLUSION: Reduction of TB incidence, prevalence, and deaths by 2015 could be achieved in most of the world, but the challenge will be greatest in Africa and Eastern Europe.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country
Dye, C., Scheele, S., >Dolin, P., Pathania, V., Raviglione, M. C., & for the WHO Global Surveillance and Monitoring Project (1999) · JAMA · doi:10.1001/jama.282.7.677 · Cited by 2,947
Self-citationThe Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553
Self-citationWorld development report 1993 : investing in health
Berkley, S., Bobadilla, J., Hecht, R., Hill, K., Jamison, D. T. T., Murray, C. J. L., Musgrove, P., Saxenian, H., & Tan, J. (1993) · Cited by 2,410
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 1×
“The ultimate tool, yet to be created, is a vaccine that has consistently high efficacy against pulmonary TB, whether or not vaccinated individuals are already infected.(49,50) In any discussion of TB control, it is vital to remember that incidence and death rates are not governed simply by drug treatment.”
BackgroundDisease Control Priorities in Developing Countries
Mosley, W. H. (1993) · World Bank, Washington, DC eBooks · doi:10.1596/0-1952-0990-7 · Cited by 1,400
Directly observed therapy for treating tuberculosis
Karumbi, J., & Garner, P. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003343.pub4 · Cited by 644
Espinal, M. A., Kim, S. J., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baéz, J., Kochi, A., Dye, C., & Raviglione, M. C. (2000) · JAMA · doi:10.1001/jama.283.19.2537 · Cited by 507
Self-citationCommunity-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, Peru
Mitnick, C., Bayona, J., Palacios, E., Shin, S., Furin, J., Alcántara, F., Sánchez, E., Sarria, M., Becerra, M., Fawzi, M. C. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022928 · Cited by 489
The intrinsic transmission dynamics of tuberculosis epidemics
Blower, S. M., Mclean, A. R., Porco, T. C., Small, P. M., Hopewell, P. C., Sanchez, M. A., & Moss, A. R. (1995) · Nature Medicine · doi:10.1038/nm0895-815 · Cited by 471
Prospects for worldwide tuberculosis control under the WHO DOTS strategy
Dye, C., Garnett, G. P., Sleeman, K., & Williams, B. G. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03199-7 · Cited by 462
Self-citationEpidemiologic basis of tuberculosis control
Rieder, H. L. (1999) · Cited by 291
Antiretroviral Drugs for Tuberculosis Control in the Era of HIV/AIDS
Williams, B. G., & Dye, C. (2003) · Science · doi:10.1126/science.1086845 · Cited by 235
Self-citationInterim policy on collaborative TB / HIV activities.
Getahun, H., van Gorkom, J., Harries, A. D., Harrington, M., & Nunn, P. (2004) · Cited by 227
Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries.
Borgdorff, M. W., Floyd, K., & Broekmans, J. F. (2002) · Europe PMC (PubMed Central) · Cited by 212
Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries
Murray, C. J. L., DeJonghe, E., Chum, H. J., Nyangulu, D. S., Salomao, A., & Styblo, K. (1991) · The Lancet · doi:10.1016/0140-6736(91)92600-7 · Cited by 191
Revised international definitions in tuberculosis control.
(2001) · PubMed · Cited by 187
Human Immunodeficiency Virus and the Prevalence of Undiagnosed Tuberculosis in African Gold Miners
Corbett, E. L., Charalambous, S., Moloi, V. M., Fielding, K., Grant, A. D., Dye, C., De Cock, K. M., Hayes, R. J., Williams, B. G., & Churchyard, G. J. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-590oc · Cited by 182
Self-citationSuárez, Floyd, Portocarrero, & Alarcon (2002) · The Lancet · Cited by 166
Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults
Johnson, J. L., Okwera, A., Hom, D. L., Mayanja‐Kizza, H., Kityo, C. M., Nsubuga, P., Nakibali, J. G., Loughlin, A. M., Yun, H. W., Mugyenyi, P. N., et al. (2001) · AIDS · doi:10.1097/00002030-200111090-00009 · Cited by 161
The Dynamics of Tuberculosis in Response to 10 Years of Intensive Control Effort in Peru
Suarez, P. G., Watt, C. J., Alarcón, E., Portocarrero, J., Zavala, D., Canales, R., Luelmo, F., Espinal, M., & Dye, C. (2001) · The Journal of Infectious Diseases · doi:10.1086/322777 · Cited by 156
Self-citationVolmink, J. A., & Garner, P. (1997) · BMJ · doi:10.1136/bmj.315.7120.1403 · Cited by 136
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults
QUIGLEY, M. A., Mwinga, A., Kitchen, M., Lisse, I. M., Fuchs, D., Porter, J. D. H., & Godfrey‐Faussett, P. (2001) · AIDS · doi:10.1097/00002030-200101260-00011 · Cited by 131
New Measurable Indicator for Tuberculosis Case Detection
Borgdorff, M. W. (2004) · Emerging infectious diseases · doi:10.3201/eid1009.040349 · Cited by 100
Scale up: meeting targets in global tuberculosis control
Elzinga, G., Raviglione, M. C., & Maher, D. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15698-5 · Cited by 92
Cost savings from alternative treatments for tuberculosis
Barnum, H. N. (1986) · Social Science & Medicine · doi:10.1016/0277-9536(86)90212-1 · Cited by 57
Developing Infectious Disease Strategies for the Developing World
Lee, J. S., & Krilov, L. R. (2006) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(06)41018-6 · Cited by 2
Cited by
Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review
Steingart, K. R., Henry, M., Ng, V., Hopewell, P. C., Ramsay, A., Cunningham, J., Urbanczik, R., Perkins, M., Aziz, M. A., & Pai, M. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70578-3 · Cited by 798
Rahier, J. F., Ben-Horin, S., Chowers, Y., Conlon, C., De Munter, P., D'Haens, G., Domènech, E., Eliakim, R., Eser, A., Frater, J., et al. (2009) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.02.010 · Cited by 738
Global epidemiology of tuberculosis
Dye, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68384-0 · Cited by 716
Self-citationTiemersma, E. W., van der Werf, M. J., Borgdorff, M. W., Williams, B. G., & Nagelkerke, N. J. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017601 · Cited by 583
“course) strategy only offer free treatment to smear-positive cases in view of their disproportionate role in tuberculosis transmission and thus their large public health impact [7].”
BackgroundSteingart, K. R., Ng, V., Henry, M., Hopewell, P. C., Ramsay, A., Cunningham, J., Urbanczik, R., Perkins, M. D., Aziz, M. A., & Pai, M. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70602-8 · Cited by 573
Metadata
- Authors
- Dye, C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-06-08
- Volume
- 293
- Issue
- 22
- Pages
- 2767
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2103640382
- Cited by
- 534
- References
- 26
- FWCI
- 35.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.